Psychedelic therapies are becoming mainstream. Deutsche Bank thinks this drug developer could triple

Leave a Comment / By Market Social / March 30, 2026

This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.

Post navigation

Analysts name ‘positive surprises’ for BTS parent company Hybe with double-digit upside

An older relative wants to give my daughter $19,000 when she turns 18. I said no. Who’s right?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

Markets

NSE (Futures & Options)
MCX
Comex
Cryptos
Forex

Trading

Intraday Trading
Margin Trading
Terms & Conditions

About Us

Why Markettrade
Become Sub Broker

333, Pali Pathar, Khar West, Mumbai, Maharashtra 400052
Pjazza Mifsud Bonnici, Marsascala, Malta
info@markettrade.live
+919769768500

ANDROID
IOS
DESKTOP

Sign Up For Real Ac.

Name * Only alphabets are allowed.

Password

Again Password

Referral (Optional)

Support Language

Whatsapp Number *

OTP